In various patient populations, the
anticoagulant dabigatran (Pradaxa) was associated with greater odds of
myocardial infarction (MI) or acute coronary syndrome than control
treatments, a meta-analysis showed.
Among randomized controlled trials for multiple indications, MI or
acute coronary syndrome occurred at a significantly higher rate with
dabigatran than with control treatment (1.19% versus 0.79%; OR 1.33, 95%
CI 1.03 to 1.71), according to Ken Uchino, MD, and Adrian Hernandez,
MD, PhD, of the Cleveland Clinic.
"Clinicians should consider the potential of these serious harmful
cardiovascular effects with use of dabigatran," they wrote online in
Archives of Internal Medicine.
Action Points
- This
study evaluated the risk of acute coronary events with the use of
dabigatran for several different clinical indications and against
different control arms.
- Dabigatran was
associated with an increased risk of myocardial infarction or acute
coronary syndrome, but the authors concluded that the risk balance of
dabigatran use appears to be favorable in patients with atrial
fibrillation because of reduction in ischemic stroke.
In the trials, dabigatran was used for stroke prevention in atrial
fibrillation (versus warfarin), prophylaxis for acute venous
thromboembolism (versus warfarin) and deep venous thrombosis (versus
enoxaparin), and prevention of events in acute coronary syndrome (versus
placebo).
"The overall benefit and risk balance of dabigatran use appears to be
favorable in patients with atrial fibrillation because of reduction in
ischemic stroke," Uchino and Hernandez wrote. "However, the cardiac risk
of dabigatran should be investigated further, especially if it is used
in populations at high risk of MI or acute coronary syndrome."
In an accompanying editorial, Jeremy Jacobs, MBBS, and Jochanan
Stessman, MD, of Hadassah-Hebrew University Medical Center in Jerusalem,
wrote, "Uchino and Hernandez suggest that physicians step back for a
moment, take their own pulse, and retain a critical view as a powerful
new drug enters clinical use on a potentially massive scale."
"The robust finding that dabigatran is associated with increased
rates of MI is alarming and emphasizes the need for continued critical
appraisal of new drugs after phase III trials," they wrote.
In the largest study of dabigatran --
the 18,000-patient RE-LY trial
-- the higher 150-mg dose of the anticoagulant was superior to
warfarin for preventing stroke and systemic embolism in patients with
atrial fibrillation. But there was also a 38% relative increase in the
risk of MI (
P=0.048).
After an additional search for events, however, the increase was no longer significant (RR 1.27, 95% CI 0.94 to 1.71).
Along the same lines,
a recently published post-hoc analysis
of the RE-LY trial showed that the risk of MI was not significantly
greater with dabigatran than with warfarin, and that the rate of overall
major adverse events was significantly lower with the higher dose of
dabigatran.
Uchino and Hernandez performed their meta-analysis to further explore
the risk of MI or acute coronary syndrome across the patient
populations in which dabigatran has been tested. For the purposes of the
analysis, patients receiving any dose of dabigatran were grouped
together.
The researchers identified seven randomized controlled trials that
included 30,514 patients -- two on preventing stroke in atrial
fibrillation, one on acute venous thromboembolism prophylaxis, one on
preventing events in acute coronary syndrome, and three on short-term
prophylaxis of deep venous thrombosis.
The control arms included warfarin, enoxaparin, or placebo.
Although dabigatran use was associated with a significantly higher
rate of MI or acute coronary syndrome, the absolute risk increase was
small -- 0.27% (95% CI 0.04% to 0.50%).
Using the revised RE-LY results instead of the originally reported
results weakened the association, although it maintained borderline
statistical significance (OR 1.27, 95% CI 1.00 to 1.61,
P=0.05).
Excluding the three short-term trials of dabigatran for prophylaxis
of deep venous thrombosis after joint replacement, the higher rate of MI
and acute coronary syndrome with the anticoagulant was significant (OR
1.33, 95% CI 1.03 to 1.72).
Uchino and Hernandez noted that they did not know of a pharmacologic
mechanism to explain the higher rate of MI or acute coronary syndrome
with dabigatran. They said that it could be a factor with dabigatran
itself or it could be that the comparator drugs are better at preventing
MI.
An important limitation of the meta-analysis is the dominant effect
of the RE-LY trial, which included more than 18,000 patients, the
researchers said. The largest of the other trials included about 3,500
patients.
In addition, patients were followed for a median of two years in RE-LY, and for six months or less in the other trials.
The study authors and the editorialists reported that they had no conflicts of interest.
From the American Heart Association: